Clinical trial · Interventional
Topotecan by Intracerebral Clysis for Recurrent Primary Malignant Brain Tumors
A Phase I Study of Topotecan by Intracerebral Clysis for the Treatment of Recurrent Primary Malignant Brain Tumors
NCT00308165CI-TRIAL-00115932completedPhase 1Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will evaluate the safety and efficacy of a chemotherapeutic drug (topotecan) as it is given directly into brain tumors by a delivery technique called convection-enhanced delivery. This drug has been used for different types of cancer, but in this study it will be given by an experimental delivery technique designed to maximize the amount of drug delivered to the brain tumor and minimize the side effects in other parts of the body. This study will also evaluate advanced magnetic resonance (MR) imaging techniques. The study will assess quality of life parameters throughout the follow-up period.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Neoplasms, Primary Malignant | Brain Neoplasm | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Convection-Enhanced Delivery | Procedure | — | UNRESOLVED |
| Topotecan | Drug | Topotecan | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Topotecan
- description
- Once a plastic catheter is placed, within 24 hours of placement, the catheter will be connected to a small pump at the bedside, and the convection-enhanced delivery of the Topotecan will begin. The Topotecan will be infused for 4 to 5 days after which time the catheters will simply be pulled out. Patients will be monitored with blood tests and MRI scans during the treatment and at different time periods during the following months.
- interventionNames
- Procedure: Convection-Enhanced Delivery
- Drug: Topotecan
Primary outcomes (2)
- measure
- Number of Participants With Dose Limiting Toxicities
- timeFrame
- During treatment, up to 5 Days
- measure
- Maximum Tolerated Dose (MTD)
- timeFrame
- During treatment, up to 5 Days
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 1 Year
Show eligibility criteria text
Inclusion Criteria: * Patients with primary malignant brain tumor, or a newly diagnosed or recurrent malignant tumor of the brainstem. Patients with tumors of the brain must have been previously treated with external beam radiation. Patients with brainstem gliomas may or may not have been previously treated. * Patients with a tumor that is stereotactically accessible (MR scan must be obtained within 30 days of enrollment and must demonstrate an enhancing mass without significant mass effect. Tumors must be less than 100 cc in total volume). * Patients who demonstrate evidence of increasing contrast enhancement on MR or CT imaging while on stable or increasing dose of steroid. * Patients with a Karnofsky Performance Score of greater than or equal to 60. * Men and women of child-bearing potential must practice birth control. Women of child bearing potential must have a negative serum or urine pregnancy test within 7 days of study entry. * Patients must possess the ability to give Informed Consent. Parent or guardian may give informed consent for minors. * Patients must be willing to and medically capable of undergoing the surgical operation. * Patients may not be receiving other investigational agents for the treatment of malignant astrocytoma. * There is no upper age limit. Patients at extreme upper end of the age spectrum will not be automatically excluded, but will be carefully scrutinized to determine their suitability for this procedure. * Patients must be at least 1 year old to participate in the study. Exclusion Criteria: * Patients with diffuse subependymal or cerebrospinal fluid (CSF) disease. * Patients with tumors involving the cerebellum, or both hemispheres. * Patients with an active infection requiring treatment or having an unexplained febrile illness. * Patients who are known HIV positive or who are known positive for Hepatitis B or C virus * Patients who have received any form of radiation or chemotherapy within 4 weeks of protocol enrollment. * Patients with systemic diseases which may be associated with unacceptable anesthetic/operative risk. * Patients who have previously received systemic topotecan for their tumor * Patients less than 1 year of age * Patients who are not able to receive an MRI scan
References
Publications (1)
- DERIVEDAnderson RC, Kennedy B, Yanes CL, Garvin J, Needle M, Canoll P, Feldstein NA, Bruce JN. Convection-enhanced delivery of topotecan into diffuse intrinsic brainstem tumors in children. J Neurosurg Pediatr. 2013 Mar;11(3):289-95. doi: 10.3171/2012.10.PEDS12142. Epub 2012 Dec 14. PMID 23240851